Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,800
- 试验地点
- 3
- 主要终点
- Prevalence of SARS CoV2 infection in PVVIH in Hauts de France
研究概览
简要总结
The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.
详细描述
On 16 March 2020, an instruction to postpone "non-urgent" consultations was given to doctors. Thus, the non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients. This change in care can have an impact on follow-up and access to treatment for PVVIH. In addition, the epidemic itself may have consequences: PVVIH may be at greater risk because of their immunosuppression and associated co-morbidities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient followed up for HIV infection in one of the COREVIH Hauts de France centres participating in the study
- •Having communicated an email address
- •Having given their consent to participate in this study
- •Beneficiary subject affiliated or entitled to a social security scheme
排除标准
- •Minor patient
- •Refusal to participate
- •Patient under guardianship
研究组 & 干预措施
experimental arm
questionnaire and follow-up visit
干预措施: questionnaire (Other)
结局指标
主要结局
Prevalence of SARS CoV2 infection in PVVIH in Hauts de France
时间窗: Inclusion
Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at inclusion in the study
次要结局
- Prevalence of SARS CoV2 infection in PVVIH in Hauts de France(through study completion, an average of 19 months)
- Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment(through study completion, an average of 19 months)
- Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment(through study completion, an average of 19 months)
- Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up(through study completion, an average of 19 months)
- Psychological consequences of this epidemic among PVVIH : HAD(through study completion, an average of 19 months)
- Psychological consequences of this epidemic among PVVIH : PROQOL-HIV(through study completion, an average of 19 months)